Levels of serum sclerostin, FGF-23, and intact parathyroid hormone in postmenopausal women treated with calcitriol
Qun Cheng,1–3 Xiaoxing Wu,1,2 Yanping Du,1–3 Wei Hong,1–3 Wenjing Tang,1–3 Huilin Li,1–3 Minmin Chen,1–3 Songbai Zheng3 1Department of Osteoporosis and Bone Disease, Huadong Hospital Affiliated to Fudan University, Shanghai, China; 2Resear...
Guardado en:
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2018
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/930ef2f4e068406cb0deaac6cc2c854f |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Qun Cheng,1–3 Xiaoxing Wu,1,2 Yanping Du,1–3 Wei Hong,1–3 Wenjing Tang,1–3 Huilin Li,1–3 Minmin Chen,1–3 Songbai Zheng3 1Department of Osteoporosis and Bone Disease, Huadong Hospital Affiliated to Fudan University, Shanghai, China; 2Research Section of Geriatric Metabolic Bone Disease, Shanghai Geriatric Institute, Shanghai, China; 3National Clinical Research Center for Aging and Medicine, Fudan University, Shanghai, China Objective: This study aimed to determine the effect of calcitriol on serum concentrations of fibroblast growth factor-23 (FGF-23), sclerostin, intact parathyroid hormone (PTH), and handgrip strength in postmenopausal women with low bone mass.Methods: A randomized, double-blind controlled trial was carried out among 141 postmenopausal women with low bone mass. Participants were randomized into two groups: 75 participants received calcitriol 0.5 μg/day and 66 participants received a placebo for 12 weeks.Results: After 12-week calcitriol treatment, significant decreases in serum intact PTH (P=0.035) and sclerostin (P=0.039), as well as significant increases in serum creatinine (P=0.027), uric acid (P=0.032), 24-hour urinary calcium (P=0.0026), and left handgrip strength (P=0.03), were observed, compared to placebo group. Level of serum sclerostin was weakly but significantly positively correlated with serum PTH (r=0.277; P=0.01) and negatively correlated with 24-hour urinary calcium (r=−0.221; P=0.04) and left handgrip strength (r=−0.338; P=0.03) after calcitriol treatment. Multiple regression analysis demonstrated that decrease in serum sclerostin was associated with decrease in PTH serum level after calcitriol treatment (OR, 7.90; 95% CI, 2.28–27.42; P=0.002). However, no significant change in FGF-23 level was observed after calcitriol treatment.Conclusion: Calcitriol treatment yields a considerable decrease in serum sclerostin and significant increase of handgrip strength, and the change in serum sclerostin is regulated by serum PTH and by muscle strength. Keywords: calcitriol, FGF-23, fibroblast growth factor 23, handgrip, intact PTH, sclerostin |
|---|